GNAI1 (P63096) variants and mutations
GNAI1 (also known as P63096) is a human protein-coding gene encoding a guanine nucleotide-binding protein G(i) subunit alpha-1 protein. It couples inhibitory G-protein-coupled receptors to downstream effectors, including suppression of adenylyl cyclase and modulation of ion channels. Pathogenic variants can disturb neuronal signaling and have been associated with developmental movement disorders and neurodevelopmental phenotypes. This analysis covers 541 GNAI1 variants and mutations. Of these, 79% have computational variant effect predictions. Disease context includes neurodevelopmental disorder with hypotonia, impaired speech, and behavioral abno, polycystic ovary syndrome, and hereditary disease. Example GNAI1 variants include M1V, G2C, and G2S.
Variant analysis overview
- Gene: GNAI1
- Protein: P63096
- UniProt accession: P63096
- Organism: Homo sapiens
- Variants analyzed: 541
- Variant scope: all variants
- Completed: 2026-08-10
Variant and mutation evidence
- Variant composition: 319 unspecified-consequence records; 136 missense variants; 65 synonymous variants; 7 frameshift variants; 7 stop-gained variants; 1 protein altering variant; 1 in-frame deletions; 2 splice-region variants; 3 substitution
- Prediction scores: 429 variants have prediction scores (79% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: neurodevelopmental disorder with hypotonia, impaired speech, and behavioral abno, polycystic ovary syndrome, hereditary disease, complex neurodevelopmental disorder, neurodegenerative disease, neurodevelopmental disorder, bacterial pneumonia, Liver abscess, Seizure, Neurodevelopmental abnormality, response to endocrine therapy, malignant renal pelvis neoplasm.
Protein structure and variant hotspots
- Protein features: 1 domains; 8 binding sites; 3 post-translational modification sites.
- Structural context: 397 variants have structural context.
- PTM context: 4 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, ClinGen, MaveDB, LitVar.
Notable GNAI1 variants
Examples include M1V, G2C, G2S, G2D, G2V, G2G, C3R, C3Y. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1V (p.Met1Val), rs2484312862, ClinGen CA368010689, ClinVar RCV003764446, Uncertain significance, Developmental disorder
- G2C (p.Gly2Cys), gnomAD 7-80135164-G-T, CADD 32.00, PolyPhen-2 0.99
- G2S (p.Gly2Ser), gnomAD 7-80135164-G-A, CADD 25.40, PolyPhen-2 0.30
- G2D (p.Gly2Asp), gnomAD 7-80135165-G-A, CADD 29.60, PolyPhen-2 0.92
- G2V (p.Gly2Val), gnomAD 7-80135165-G-T, CADD 29.40, PolyPhen-2 0.94
- G2G (p.Gly2Gly), rs145033896, gnomAD 7-80135166-C-A, CADD 14.60
- C3R (p.Cys3Arg), gnomAD 7-80135167-T-C, MetaLR 0.84, MetaSVM 0.86
- C3Y (p.Cys3Tyr), gnomAD 7-80135168-G-A, MetaLR 0.85, MetaSVM 0.95
- C3F (p.Cys3Phe), gnomAD 7-80135168-G-T, MetaLR 0.84, MetaSVM 0.88
- C3C (p.Cys3Cys), gnomAD 7-80135169-C-T, CADD 13.80
- C3* (p.Cys3Ter), gnomAD 7-80135169-C-A, CADD 35.00
- T4R (p.Thr4Arg), gnomAD 7-80135169-CA-C, CADD 29.60
- T4A (p.Thr4Ala), gnomAD 7-80135170-A-G, MetaLR 0.38, MetaSVM -0.55
- T4M (p.Thr4Met), gnomAD 7-80135171-C-T, MetaLR 0.50, MetaSVM -0.20
- T4K (p.Thr4Lys), gnomAD 7-80135171-C-A, MetaLR 0.58, MetaSVM 0.05
- T4T (p.Thr4Thr), gnomAD 7-80135172-G-C, CADD 14.40
- L5P (p.Leu5Pro), rs1224009797, ClinGen CA368010720, ClinVar RCV001758457, TOPMed rs1224009797, CADD 23.70, PolyPhen-2 0.01, Uncertain significance, not provided
- L5M (p.Leu5Met), gnomAD 7-80135173-C-A, MetaLR 0.46, MetaSVM -0.59
- L5L (p.Leu5Leu), gnomAD 7-80135173-C-T, CADD 14.10
- S6R (p.Ser6Arg), TOPMed rs1162724911, gnomAD rs1162724911, CADD 26.30, PolyPhen-2 0.98
- S6G (p.Ser6Gly), gnomAD 7-80135176-A-G, MetaLR 0.71, MetaSVM 0.50
- S6C (p.Ser6Cys), gnomAD 7-80135176-A-T, MetaLR 0.84, MetaSVM 0.87
- S6N (p.Ser6Asn), gnomAD 7-80135177-G-A, MetaLR 0.72, MetaSVM 0.55
- S6S (p.Ser6Ser), rs1162724911, gnomAD 7-80135178-C-T, CADD 15.70
- A7T (p.Ala7Thr), rs773988706, ClinGen CA4314405, ClinVar RCV003258370, ExAC rs773988706, CADD 22.80, PolyPhen-2 0.00, Likely benign, Inborn genetic diseases
- A7S (p.Ala7Ser), gnomAD 7-80135179-G-T, MetaLR 0.53, MetaSVM -0.19
- A7V (p.Ala7Val), gnomAD 7-80135180-C-T, MetaLR 0.58, MetaSVM -0.06
- A7D (p.Ala7Asp), gnomAD 7-80135180-C-A, MetaLR 0.58, MetaSVM -0.05
- A7A (p.Ala7Ala), gnomAD 7-80135181-C-A, CADD 15.20
- E8A (p.Glu8Ala), TOPMed rs1293940480, gnomAD rs1293940480, CADD 25.00, PolyPhen-2 0.01
- E8V (p.Glu8Val), TOPMed rs1293940480, gnomAD rs1293940480, CADD 25.20, PolyPhen-2 0.00
- E8Q (p.Glu8Gln), gnomAD 7-80135182-G-C, MetaLR 0.64, MetaSVM 0.12
- E8K (p.Glu8Lys), gnomAD 7-80135182-G-A, MetaLR 0.62, MetaSVM 0.08
- E8* (p.Glu8Ter), gnomAD 7-80135182-G-T, CADD 39.00
- E8G (p.Glu8Gly), gnomAD 7-80135183-A-G, MetaLR 0.56, MetaSVM -0.13
- E8D (p.Glu8Asp), gnomAD 7-80135184-G-T, MetaLR 0.47, MetaSVM -0.47
- E8E (p.Glu8Glu), rs368816280, gnomAD 7-80135184-G-A, CADD 14.90
- D9E (p.Asp9Glu), ExAC rs760895601, TOPMed rs760895601, gnomAD rs760895601, CADD 18.40, PolyPhen-2 0.01
- D9N (p.Asp9Asn), gnomAD rs1397814226, CADD 24.30, PolyPhen-2 0.05
- D9Y (p.Asp9Tyr), gnomAD 7-80135185-G-T, MetaLR 0.75, MetaSVM 0.62
- D9G (p.Asp9Gly), gnomAD 7-80135186-A-G, MetaLR 0.59, MetaSVM -0.05
- D9D (p.Asp9Asp), rs760895601, gnomAD 7-80135187-C-T, CADD 14.70
- K10* (p.Lys10Ter), NCI-TCGA Cosmic COSV6352, Variant assessed as somatic; high impact.
- K10R (p.Lys10Arg), gnomAD 7-80135187-CA-C, CADD 32.00
- K10E (p.Lys10Glu), gnomAD 7-80135188-A-G, MetaLR 0.56, MetaSVM -0.28
- K10M (p.Lys10Met), gnomAD 7-80135189-A-T, MetaLR 0.65, MetaSVM -0.00
- K10T (p.Lys10Thr), gnomAD 7-80135189-A-C, MetaLR 0.58, MetaSVM -0.21
- K10N (p.Lys10Asn), gnomAD 7-80135190-G-T, MetaLR 0.63, MetaSVM -0.01
- K10K (p.Lys10Lys), rs1787387463, gnomAD 7-80135190-G-A, CADD 15.00
- A11E (p.Ala11Glu), gnomAD rs1340678679, CADD 20.80, PolyPhen-2 0.01
- A11V (p.Ala11Val), gnomAD rs1340678679, CADD 23.20, PolyPhen-2 0.00
- A11S (p.Ala11Ser), gnomAD 7-80135191-G-T, MetaLR 0.60, MetaSVM 0.01
- A11T (p.Ala11Thr), gnomAD 7-80135191-G-A, MetaLR 0.63, MetaSVM 0.10
- A11G (p.Ala11Gly), gnomAD 7-80135191-GC-G, CADD 32.00
- A11A (p.Ala11Ala), gnomAD 7-80135193-G-A, CADD 15.70
- A12T (p.Ala12Thr), gnomAD 7-80135194-G-A, MetaLR 0.63, MetaSVM 0.12
- A12S (p.Ala12Ser), gnomAD 7-80135194-G-T, MetaLR 0.60, MetaSVM 0.02
- A12E (p.Ala12Glu), gnomAD 7-80135195-C-A, MetaLR 0.66, MetaSVM 0.21
- A12V (p.Ala12Val), gnomAD 7-80135195-C-T, MetaLR 0.75, MetaSVM 0.78
- A12A (p.Ala12Ala), rs764470544, gnomAD 7-80135196-G-A, CADD 15.30
- V13L (p.Val13Leu), rs1433259734, ClinGen CA368010771, ClinVar RCV002280509, ClinVar RCV005574924, CADD 22.70, PolyPhen-2 0.00, Uncertain significance, not provided; Inborn genetic diseases
- V13M (p.Val13Met), gnomAD 7-80135197-G-A, MetaLR 0.54, MetaSVM -0.17
- V13A (p.Val13Ala), gnomAD 7-80135198-T-C, MetaLR 0.34, MetaSVM -0.75
- V13V (p.Val13Val), gnomAD 7-80135199-G-A, CADD 15.40
- E14* (p.Glu14Ter), gnomAD 7-80135200-G-T, CADD 40.00
- E14G (p.Glu14Gly), gnomAD 7-80135201-A-G, MetaLR 0.58, MetaSVM -0.18
- E14E (p.Glu14Glu), gnomAD 7-80135202-G-A, CADD 14.70
- R15W (p.Arg15Trp), ExAC rs776765120, TOPMed rs776765120, gnomAD rs776765120, CADD 30.00, PolyPhen-2 0.95
- R15R (p.Arg15Arg), gnomAD 7-80135203-C-A, CADD 15.80
- R15Q (p.Arg15Gln), gnomAD 7-80135204-G-A, MetaLR 0.60, MetaSVM -0.07
- S16G (p.Ser16Gly), gnomAD 7-80135206-A-G, MetaLR 0.70, MetaSVM 0.19
- S16R (p.Ser16Arg), gnomAD 7-80135208-T-G, MetaLR 0.81, MetaSVM 0.58
- K17E (p.Lys17Glu), TOPMed rs1787387719, CADD 23.80, PolyPhen-2 0.29
- K17N (p.Lys17Asn), NCI-TCGA Cosmic COSV6352, Variant assessed as somatic; moderate impact.
- K17R (p.Lys17Arg), 1000Genomes rs554748156, ExAC rs554748156, TOPMed rs554748156, gnomAD rs554748156, CADD 23.30, PolyPhen-2 0.01
- M18V (p.Met18Val), gnomAD 7-80135212-A-G, MetaLR 0.44, MetaSVM -0.54
- p.Met18delinsThrVal, gnomAD 7-80135212-A-ACTG, CADD 29.40
- M18T (p.Met18Thr), gnomAD 7-80135213-T-C, MetaLR 0.42, MetaSVM -0.48
- M18I (p.Met18Ile), gnomAD 7-80135214-G-T, MetaLR 0.44, MetaSVM -0.39
- I19V (p.Ile19Val), gnomAD 7-80135215-A-G, MetaLR 0.69, MetaSVM 0.16
- I19T (p.Ile19Thr), gnomAD 7-80135216-T-C, MetaLR 0.84, MetaSVM 0.88
- I19I (p.Ile19Ile), rs147129497, gnomAD 7-80135217-C-T, CADD 15.70
- D20G (p.Asp20Gly), gnomAD 7-80135219-A-G, MetaLR 0.78, MetaSVM 0.51
- D20D (p.Asp20Asp), rs767309821, gnomAD 7-80135220-C-T, CADD 15.20
- R21H (p.Arg21His), NCI-TCGA Cosmic COSV1006, TOPMed rs1787387941, CADD 25.40, PolyPhen-2 0.49, Variant assessed as somatic; moderate impact.
- R21C (p.Arg21Cys), gnomAD 7-80135221-C-T, MetaLR 0.73, MetaSVM 0.41
- R21S (p.Arg21Ser), gnomAD 7-80135221-C-A, MetaLR 0.57, MetaSVM -0.16
- R21L (p.Arg21Leu), gnomAD 7-80135222-G-T, MetaLR 0.64, MetaSVM 0.30
- R21R (p.Arg21Arg), gnomAD 7-80135223-C-T, CADD 13.80
- N22Y (p.Asn22Tyr), gnomAD 7-80135224-A-T, MetaLR 0.60, MetaSVM -0.01
- N22D (p.Asn22Asp), gnomAD 7-80135224-A-G, MetaLR 0.48, MetaSVM -0.49
- N22K (p.Asn22Lys), gnomAD 7-80135226-C-A, MetaLR 0.41, MetaSVM -0.46
- N22N (p.Asn22Asn), rs752712803, gnomAD 7-80135226-C-T, CADD 13.60
- L23F (p.Leu23Phe), gnomAD 7-80135227-C-T, MetaLR 0.78, MetaSVM 0.71
- L23I (p.Leu23Ile), gnomAD 7-80135227-C-A, MetaLR 0.49, MetaSVM -0.41
- L23P (p.Leu23Pro), gnomAD 7-80135228-T-C, MetaLR 0.83, MetaSVM 0.85
- L23L (p.Leu23Leu), rs755800667, gnomAD 7-80135229-C-A, CADD 9.93
- R24S (p.Arg24Ser), gnomAD 7-80135230-C-A, MetaLR 0.59, MetaSVM -0.03
- R24C (p.Arg24Cys), gnomAD 7-80135230-C-T, MetaLR 0.82, MetaSVM 0.87
- R24H (p.Arg24His), gnomAD 7-80135231-G-A, MetaLR 0.68, MetaSVM 0.41
- R24L (p.Arg24Leu), gnomAD 7-80135231-G-T, MetaLR 0.57, MetaSVM -0.07
- R24R (p.Arg24Arg), gnomAD 7-80135232-T-C, CADD 8.06
- E25Q (p.Glu25Gln), TOPMed rs1787388145
- E25* (p.Glu25Ter), gnomAD 7-80135233-G-T, CADD 37.00
- E25K (p.Glu25Lys), gnomAD 7-80135233-G-A, MetaLR 0.44, MetaSVM -0.40
- E25G (p.Glu25Gly), gnomAD 7-80135234-A-G, MetaLR 0.69, MetaSVM 0.26
- E25E (p.Glu25Glu), rs1264210493, gnomAD 7-80135235-G-A, CADD 11.50
- E25D (p.Glu25Asp), gnomAD 7-80135235-G-T, MetaLR 0.58, MetaSVM -0.15
- D26A (p.Asp26Ala), TOPMed rs886804159, gnomAD rs886804159, CADD 23.80, PolyPhen-2 0.01, Uncertain significance, not provided
- D26N (p.Asp26Asn), gnomAD 7-80135236-G-A, MetaLR 0.75, MetaSVM 0.58
- D26Y (p.Asp26Tyr), gnomAD 7-80135236-G-T, MetaLR 0.84, MetaSVM 0.90
- D26G (p.Asp26Gly), gnomAD 7-80135237-A-G, MetaLR 0.64, MetaSVM 0.07
- D26E (p.Asp26Glu), gnomAD 7-80135238-C-A, MetaLR 0.39, MetaSVM -0.78
- D26D (p.Asp26Asp), rs777727070, gnomAD 7-80135238-C-T, CADD 8.66
- G27S (p.Gly27Ser), gnomAD rs1180244878, CADD 22.90, PolyPhen-2 0.27
- G27C (p.Gly27Cys), gnomAD 7-80135239-G-T, MetaLR 0.82, MetaSVM 0.85
- G27A (p.Gly27Ala), gnomAD 7-80135240-G-C, MetaLR 0.45, MetaSVM -0.38
- G27V (p.Gly27Val), gnomAD 7-80135240-G-T, MetaLR 0.77, MetaSVM 0.73
- G27D (p.Gly27Asp), gnomAD 7-80135240-G-A, MetaLR 0.62, MetaSVM 0.26
- G27G (p.Gly27Gly), gnomAD 7-80135241-C-A, CADD 9.11
- E28* (p.Glu28Ter), gnomAD 7-80135242-G-T, CADD 38.00
- E28K (p.Glu28Lys), gnomAD 7-80135242-G-A, MetaLR 0.42, MetaSVM -0.43
- E28G (p.Glu28Gly), gnomAD 7-80135243-A-G, MetaLR 0.59, MetaSVM 0.10
- E28E (p.Glu28Glu), rs749155882, gnomAD 7-80135244-G-A, CADD 12.30
- E28D (p.Glu28Asp), gnomAD 7-80135244-G-C, MetaLR 0.46, MetaSVM -0.40
- K29R (p.Lys29Arg), gnomAD 7-80135244-GA-G, CADD 28.00
- K29E (p.Lys29Glu), gnomAD 7-80135245-A-G, MetaLR 0.54, MetaSVM -0.19
- K29M (p.Lys29Met), gnomAD 7-80135246-A-T, MetaLR 0.56, MetaSVM -0.15
- K29K (p.Lys29Lys), gnomAD 7-80135247-G-A, CADD 12.40
- K29N (p.Lys29Asn), gnomAD 7-80135247-G-T, MetaLR 0.49, MetaSVM -0.35
- A30G (p.Ala30Gly), gnomAD 7-80135249-C-G, MetaLR 0.63, MetaSVM 0.11
- A30V (p.Ala30Val), gnomAD 7-80135249-C-T, MetaLR 0.60, MetaSVM 0.02
- A30E (p.Ala30Glu), gnomAD 7-80135249-C-A, MetaLR 0.52, MetaSVM -0.19
- A30A (p.Ala30Ala), rs140693023, gnomAD 7-80135250-G-A, CADD 13.00
- A31T (p.Ala31Thr), gnomAD 7-80135251-G-A, MetaLR 0.60, MetaSVM 0.00
- A31S (p.Ala31Ser), gnomAD 7-80135251-G-T, MetaLR 0.48, MetaSVM -0.31
- A31E (p.Ala31Glu), gnomAD 7-80135252-C-A, MetaLR 0.61, MetaSVM 0.02
- A31V (p.Ala31Val), gnomAD 7-80135252-C-T, MetaLR 0.60, MetaSVM -0.01
- A31A (p.Ala31Ala), gnomAD 7-80135253-G-T, CADD 13.20
- R32C (p.Arg32Cys), gnomAD 7-80135254-C-T, MetaLR 0.48, MetaSVM 0.03
- R32S (p.Arg32Ser), gnomAD 7-80135254-C-A, MetaLR 0.23, MetaSVM -0.81
- R32L (p.Arg32Leu), gnomAD 7-80135255-G-T, MetaLR 0.32, MetaSVM -0.61
- R32H (p.Arg32His), gnomAD 7-80135255-G-A, MetaLR 0.39, MetaSVM -0.33
- R32R (p.Arg32Arg), gnomAD 7-80135256-C-G, CADD 10.30
- E33D (p.Glu33Asp), gnomAD rs1417639782, CADD 22.50, PolyPhen-2 0.01
- E33K (p.Glu33Lys), NCI-TCGA TCGA novel, Ensembl rs1583996658, CADD 24.40, PolyPhen-2 0.45, Variant assessed as somatic; moderate impact.
- E33* (p.Glu33Ter), gnomAD 7-80135257-G-T, CADD 38.00
- E33V (p.Glu33Val), gnomAD 7-80135258-A-T, MetaLR 0.53, MetaSVM -0.35
- E33G (p.Glu33Gly), gnomAD 7-80135258-A-G, MetaLR 0.63, MetaSVM -0.05
- E33E (p.Glu33Glu), rs1417639782, gnomAD 7-80135259-G-A, CADD 12.70
- V34F (p.Val34Phe), gnomAD 7-80135260-G-T, MetaLR 0.75, MetaSVM 0.60
- V34I (p.Val34Ile), gnomAD 7-80135260-G-A, MetaLR 0.48, MetaSVM -0.33
- V34A (p.Val34Ala), gnomAD 7-80135261-T-C, MetaLR 0.70, MetaSVM 0.28
- V34G (p.Val34Gly), gnomAD 7-80135261-T-G, MetaLR 0.82, MetaSVM 0.74
- V34V (p.Val34Val), gnomAD 7-80135262-C-A, CADD 18.70
- K35E (p.Lys35Glu), gnomAD 7-80135263-A-G, MetaLR 0.58, MetaSVM 0.17
- K35M (p.Lys35Met), gnomAD 7-80135264-A-T, MetaLR 0.67, MetaSVM 0.31
- K35R (p.Lys35Arg), gnomAD 7-80135264-A-G, MetaLR 0.35, MetaSVM -0.52
- K35K (p.Lys35Lys), rs1035649714, gnomAD 7-80135265-G-A, CADD 14.40
- K35N (p.Lys35Asn), gnomAD 7-80135265-G-T, MetaLR 0.71, MetaSVM 0.67
- L36L (p.Leu36Leu), rs1787388734, gnomAD 7-80135266-C-T, CADD 14.90
- L36M (p.Leu36Met), gnomAD 7-80135266-C-A, MetaLR 0.57, MetaSVM 0.17
- L36P (p.Leu36Pro), gnomAD 7-80135267-T-C, MetaLR 0.69, MetaSVM 0.37
- L37M (p.Leu37Met), gnomAD 7-80135269-C-A, MetaLR 0.94, MetaSVM 1.09
- L37L (p.Leu37Leu), rs771630216, gnomAD 7-80135269-C-T, CADD 15.20
- L37P (p.Leu37Pro), gnomAD 7-80135270-T-C, MetaLR 0.94, MetaSVM 0.95
- L38M (p.Leu38Met), gnomAD 7-80135272-C-A, MetaLR 0.62, MetaSVM 0.57
- L38L (p.Leu38Leu), gnomAD 7-80135272-C-T, CADD 16.10
- L38P (p.Leu38Pro), gnomAD 7-80135273-T-C, MetaLR 0.70, MetaSVM 0.63
- L39=, rs372783127, NCI-TCGA Cosmic COSV1006, Variant assessed as somatic; low impact.
- L39del (p.Leu39del), rs1157784002, gnomAD 7-80135264-AGCT-A, CADD 22.60
- L39V (p.Leu39Val), gnomAD 7-80135275-C-G, MetaLR 0.90, MetaSVM 0.96
- L39I (p.Leu39Ile), gnomAD 7-80135275-C-A, MetaLR 0.88, MetaSVM 0.83
- L39F (p.Leu39Phe), gnomAD 7-80135275-C-T, MetaLR 0.91, MetaSVM 1.01
- L39P (p.Leu39Pro), gnomAD 7-80135276-T-C, MetaLR 0.91, MetaSVM 0.93
- L39L (p.Leu39Leu), rs372783127, gnomAD 7-80135277-C-G, CADD 12.70
- G40C (p.Gly40Cys), rs2116052322, ClinGen CA368010953, ClinVar RCV002249061, Ensembl rs2116052322, AlphaMissense 1.00, MetaLR 0.97, Likely pathogenic, Neurodevelopmental disorder with hypotonia, impaired speech, and behavioral abno
- G40R (p.Gly40Arg), rs2116052322, ClinGen CA368010952, ClinVar RCV003325401, UniProt VAR 087205, AlphaMissense 1.00, MetaLR 0.97, Pathogenic, not provided
- G40S (p.Gly40Ser), NCI-TCGA TCGA novel, CADD 35.00, PolyPhen-2 0.87, Variant assessed as somatic; moderate impact., in NEDHISB
- G40D (p.Gly40Asp), gnomAD 7-80188951-G-A, MetaLR 0.98, MetaSVM 1.06
Public GNAI1 analysis runs
- GNAI1 analysis run — GNAI1 (541 variants) — completed 2026-08-10